Sign in

CIK 0001321834

  • Non-accelerated filer
  • Smaller reporting company

Q/C TECHNOLOGIES, INC.

Sign in to watch
Ticker
QCLS
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 856-848-8698
Business address
1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK, NY, 10036
Former names
Q/C TECHNOLOGIES, INC., TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., Akers Biosciences Inc
  1. 4 Option exercise Director acquired 5,201 shares (option exercise)
  2. 4 Option exercise Director acquired 5,201 shares (option exercise)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Grant or award CEO, CFO acquired 3,750 shares (grant or award)
  5. 4 Grant or award CEO, CFO acquired 3,750 shares (grant or award)
  6. 4 Grant or award CEO, CFO acquired 3,750 shares (grant or award)
  7. 4 Grant or award CEO, CFO acquired 3,750 shares (grant or award)
  8. 4 Grant or award CEO, CFO acquired 7,500 shares (grant or award)
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Grant or award CEO, CFO acquired 15,000 shares (grant or award)
  13. 4 Grant or award CEO, CFO acquired 7,500 shares (grant or award)
  14. 3 Insider Initial Statement of Ownership
  15. 3 Insider Initial Statement of Ownership
  16. 3 Insider Initial Statement of Ownership
  17. 4/A Grant or award Chief Executive Officer acquired 150,000 shares (grant or award)
  18. 4/A Grant or award Chief Executive Officer acquired 27,500 shares (grant or award)
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 5 of 7 · 132 filings